Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.73 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.73 |
| ▸ | PRKCG | P05129 | 2/20 | 0.73 |
| ▸ | PRKCB | P05771 | 2/20 | 0.73 |
| ▸ | PRKCA | P17252 | 2/20 | 0.73 |
| ▸ | PRKCH | P24723 | 2/20 | 0.73 |
| ▸ | PRKCI | P41743 | 2/20 | 0.73 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.73 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.73 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.73 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.73 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | GMNN | O75496 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447847 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL27603790 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL12380305 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL29464127 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL8257173 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| Edelfosine SCHEMBL8251942 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL23016734 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| Edelfosine SCHEMBL4177817 | 1.00 | AKT1 (0.73) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| Edelfosine SCHEMBL28728461 | 0.94 | AKT1 (0.65) | AKT1PRKD3PRKCGPRKCBPRKCA | |
| Edelfosine SCHEMBL28728460 | 0.94 | AKT1 (0.65) | AKT1PRKD3PRKCGPRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260005070-A1 | DICING SYSTEM AND DICING METHOD | PANASONIC IP MAN CO LTD (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12438051-B2 | Dicing system and dicing method | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-12185150-B2 | Communication apparatus and communication method for measuring a channel quality indicator (CQI) | SUN PATENT TRUST (US) | 2024-12-31 | — | — | US | disclosed |
| CN-117935825-A | Interactive unrestricted voice enhancement method, system and terminal based on ultrasonic sensing | 上海交通大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20240114377-A1 | COMMUNICATION APPARATUS AND COMMUNICATION METHOD FOR MEASURING A CHANNEL QUALITY INDICATOR (CQI) | SUN PATENT TRUST (US) | 2024-04-04 | — | — | US | disclosed |
| US-11889340-B2 | Communication apparatus and communication method for measuring a channel quality indicator (CQI) | SUN PATENT TRUST (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230189043-A1 | COMMUNICATION APPARATUS AND COMMUNICATION METHOD FOR MEASURING A CHANNEL QUALITY INDICATOR (CQI) | SUN PATENT TRUST (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023086465-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11582630-B2 | Communication apparatus and communication method for measuring a channel quality indicator (CQI) | SUN PATENT TRUST (US) | 2023-02-14 | — | — | US | disclosed |
| US-11529361-B2 | Halogenated salicylanilides for treating Clostridium infections | UNION therapeutics A/S (DK) | 2022-12-20 | — | — | US | disclosed |
| WO-2022249226-A1 | ROBOT TEACHING DEVICE, ROBOT CONTROL SYSTEM, ROBOT TEACHING METHOD, AND ROBOT TEACHING PROGRAM | 三菱電機株式会社 | 2022-12-01 | — | — | WO | disclosed |
| WO-2022244577-A1 | ILLUMINATION ADJUSTING DEVICE, ILLUMINATION ADJUSTING METHOD, AND PRODUCT RECOGNITION SYSTEM | パナソニックＩＰマネジメント株式会社 | 2022-11-24 | — | — | WO | disclosed |
| CN-114450779-A | Cutting system and cutting method | 松下知识产权经营株式会社 | 2022-05-06 | — | — | CN | disclosed |
| US-20110144137-A1 | METHOD FOR PREVENTING OR ALLEVIATING THE NOXIOUS EFFECTS RESULTING FROM TOXICANT EXPOSURE | YALE UNIVERSITY (US) | 2011-06-16 | — | — | US | disclosed |
| CN-101439016-A | Bendamustine and potentiating agent thereof carried by anti-cancer medicine sustained-release injection | JINAN SHUAIHUA PHARMACEUTICAL (CN) | 2009-05-27 | — | — | CN | disclosed |
| CN-101332181-A | Anticancer composition containing irinotecan | JINAN SHUAIHUA MEDICINE SCIENC (CN) | 2008-12-31 | — | — | CN | disclosed |
| CN-101229117-A | Thermostatic sustained release injection containing phosphatidylinositol 3-genistein inhibitor and preparing method thereof | SHANDONG LANJIN PHARMACEUTICAL (CN) | 2008-07-30 | — | — | CN | disclosed |
| CN-101019828-A | Anticancer composition containing both phosphoinositide-3-kinase inhibitor and hormone medicine | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2007-08-22 | — | — | CN | disclosed |
| CN-101019830-A | Anticancer composition containing phosphoinositide 3-kinase inhibitor and topoisomerase inhibitor | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2007-08-22 | — | — | CN | disclosed |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | AKT1 2500/4885PRKD3 4274/4885PRKCG 1674/4885 |
| US-20260005070-A1 | DICING SYSTEM AND DICING METHOD | CAD, DSG1, MATR3 | AKT1 3547/4885PRKD3 3099/4885PRKCG 2621/4885 |
| US-11529361-B2 | Halogenated salicylanilides for treating Clostridium infections | SLC10A2, FABP2, SI | AKT1 3922/4885PRKD3 1515/4885PRKCG 3566/4885 |
| US-20110144137-A1 | METHOD FOR PREVENTING OR ALLEVIATING THE NOXIOUS EFFECTS RESULTING FROM TOXICANT EXPOSURE | TRPA1, HRH2, HRH4 | AKT1 3695/4885PRKD3 1941/4885PRKCG 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.